Loading...
TrendSpott

TrendSpott

TrendSpott
 
 
Bristol-Myers Squibb
69.31
+1.61%
 
Recommendation
BMY Bristol-Myers Squibb
  Login
 
 
Last Price
 
Change
 
69.31
 
+1.61%
 
 

 
Sentiment
 
  Login to display
 
 

71.22

73

78.86

76.82

 
 
1m
3m
6m
1y
 

Summary

  Login to display Bristol-Myers Squibb (BMY) recommendation from the last 90 days from financial news and social media.
 

Rewards

Rewards

 Earnings are forecast to grow

Rewards

 Trading below its fair value

 
 

Risk Level

 
TrendSpott
 

Bristol-Myers Squibb (BMY) has Low Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 
Earnings ×
 

Earnings

3.20
 

TrendSpott

 Above analyst estimates

TrendSpott

 Sales decline

TrendSpott

 Earnings decline YoY

 
 
Rating ×
 

Rating

NA
 
 
Momentum ×
 

Momentum

3.11
 

TrendSpott

 Price value has negative momentum

 
Activity ×
 

Activity

3.70
 
 
Future ×
 

Future

4.38
 

TrendSpott

 Earnings are forecast to grow

TrendSpott

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is negative and it remained unchanged from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
75%
NA
44%
88%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
75%
20%
Positive
Negative
41 out of 55
events present
11 out of 55
events present
 

 
Events Calendar
Click for more information
 
February
S
M
T
W
T
F
S
March
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Options Activity
1 Day Ago
69.31
+1.61%
 
Options Activity
This Week
68.20
+0.03%
 
Investors Activity
3 Weeks Ago
68.00
-1.31%
 
Dividend Declares
3 Weeks Ago
69.30
+0.16%
 
Strong Earnings
2 Month Ago
72.77
+2.16%
 
Top Headlines

unusual put option trade in bristol-myers squibb (bmy) worth $726.85k. on march 31 2023 at 13:15:02 et an unusually large $726.85k block of put contracts in bristol-myers squibb (bmy) was bought with a s

Fri Mar 31, 2023

Momentum

unusual call option trade in bristol-myers squibb (bmy) worth $534.73k. on march 30 2023 at 13:08:53 et an unusually large $534.73k block of call contracts in bristol-myers squibb (bmy) was bought with a

Thu Mar 30, 2023

Momentum

bristol myers squibb (bmy) gains as market dips: what you should know. bristol myers squibb (bmy) closed the most recent trading day at $68.20 moving 0.19% from the previous trading session. the stock outpaced the s&.p 500s daily lo

Tue Mar 28, 2023

Momentum

bristol myers (bmy) gets approval of psoriasis drug in eu. bristol myers squibb bmy announced that the european commission approved sotyktu (deucravacitinib) for treating adults with moderate-to-severe plaque psoriasis who are candidat

Tue Mar 28, 2023

Activity

evotec stock up as it extends neurodegeneration partnership with bristol myers squibb. (rttnews) - shares of evotec se (evo) were gaining around 4 percent in the german trading after the drug maker announced tuesday that it has extended and expa

Tue Mar 28, 2023

Activity
Momentum

bristol myers psoriasis drug sotyktu gets approval in eu.

Tue Mar 28, 2023

Activity

evotec gets $50m upfront from bristol myers in pact to develop neuro disease drugs.

Tue Mar 28, 2023

Activity

bristol-myers squibb: nobody panic! share price stumble shouldnt last.

Mon Mar 27, 2023

Momentum

eterna therapeutics reports financial results for fourth quarter and full year 2022 and recent business highlights.

– execute

Mon Mar 20, 2023

Activity

best-selling drugs by bristol myers pfizer abbvie likely candidates for us price negotiation. ) eliquis) ibrance and) imbruvica are expected to be among the ten top-selling drugs subject to United States

Mon Mar 13, 2023

Activity

bristol myers pfizer abbvie drugs likely to face United States price negotiation. the blood thinner eliquis from bristol myers squibb pfizers breast cancer drug ibrance and abbvies leukemia treatment imbruvica are likely to be among 10 big-selli

Mon Mar 13, 2023

Activity

bristol-myers squibb (bmy) declares $0.57 dividend. bristol-myers squibb said on march 3 2023 that its board of directors declared a regular quarterly dividend of $0.57 per share ($2.28 annualized). previous

Tue Mar 7, 2023

Activity

bristol-myers squibb company (bmy) presents at cowen 43rd annual healthcare conference (transcript).

Tue Mar 7, 2023

Activity

bristol myers (bmy) gets eu nod for anemia drug reblozyl. bristol myers squibbbmy announced that the european commission (eu) has granted full marketing authorization to reblozyl (luspatercept) for the treatments of anemia associated w

Mon Mar 6, 2023

Activity

bristol-myers squibb company  declares $0.57 dividend.

Fri Mar 3, 2023

Activity

bristol myers viz.ai team up to deploy ai tool to detect heart disease.

Fri Mar 3, 2023

Activity

bristol-myers janssen launch late-stage librexia program evaluating milvexian.

Thu Mar 2, 2023

Activity

bristol myers wins $6.4b lawsuit linked to cvr in celgene acquisition.

Thu Mar 2, 2023

Activity

bristol myers janssen launch late-stage librexia program evaluating milvexian.

Thu Mar 2, 2023

Activity

bristol myers: looking good for 2023.

Tue Feb 21, 2023

Potential

bristol myers opdivo shows improved clinical benefits in bladder cancer at three years. ) announced

Fri Feb 17, 2023

Potential

why bristol myers squibb (bmy) is a top value stock for the long-term. taking full advantage of the stock market and investing with confidence are common goals for new and old investors and zacks premium offers many different ways to d

Fri Feb 17, 2023

Potential

a bearish sign appears on bristol-myers squibbs chart. if history is any guide there may be trouble ahead for shares of ). a so-called death cross has formed on its chart and not surprisingly this could be bearish for the stock. when a shorter-term av

Mon Feb 13, 2023

Momentum
Potential

bristol myers profit beats on better-than-feared revlimid sales. bristol myers squibb co on thursday reported quarterly earnings that beat analysts estimates due to a smaller-than-expected drop in sales of cancer drug revlimid which is facing co

Thu Feb 2, 2023

Earnings
Earnings
Potential

bristol myers squibb (bmy) q4 earnings and revenues surpass estimates. bristol myers squibb (bmy) came out with quarterly earnings of $1.82 per share beating the zacks consensus estimate of $1.71 per share. this compares to earnings of

Thu Feb 2, 2023

Earnings

bristol-myers squibb guides fy23 adj. eps in line. q4 results top estimates. (rttnews) - while reporting financial results for the fourth quarter on thursday biopharmaceutical company bristol-myers squibb co. (bmy) provided earnings adjusted ear

Thu Feb 2, 2023

Earnings

bristol myers squibb (bmy) stock sinks as market gains: what you should know. bristol myers squibb (bmy) closed the most recent trading day at $72.45 moving -0.74% from the previous trading session. this move lagged the s&.p 500s da

Fri Jan 27, 2023

Momentum

bristol myers wins eu backing to expand label for anemia therapy.

Fri Jan 27, 2023

Activity

earnings preview: bristol myers squibb (bmy) q4 earnings expected to decline. wall street expects a year-over-year decline in earnings on lower revenues when bristol myers squibb (bmy) reports results for the quarter ended december 202

Thu Jan 26, 2023

Earnings

bristol myers squibbs new products need more insurance coverage but still a buy.

Wed Jan 18, 2023

Activity
Potential

 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss
 

Receive our daily BMY alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
TrendSpott

TrendSpott

Get the pulse of the market

 
TrendSpott

TrendSpott

BMY Bristol-Myers Squibb

Last Price
69.31
Change
+1.61%
Recommendation
  Login to display
 

Summary

  Login to display Bristol-Myers Squibb (BMY) recommendation from the last 90 days from financial news and social media.

 
 
71.22
73
78.86
76.82
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Rewards

Rewards

 Earnings are forecast to grow

Rewards

 Trading below its fair value

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
NA
44%
88%
On Track
On Track
On Track
 
75%
20%
Positive
Negative
41 out of 55
events present
11 out of 55
events present
 

Street Opinion

Street view is bullish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 
Earnings ×
 

Earnings

3.20
 

TrendSpott

 Above analyst estimates

TrendSpott

 Sales decline

TrendSpott

 Earnings decline YoY

 
 
Rating ×
 

Rating

NA
 
 
Momentum ×
 

Momentum

3.11
 

TrendSpott

 Price value has negative momentum

 
Activity ×
 

Activity

3.70
 
 
Future ×
 

Future

4.38
 

TrendSpott

 Earnings are forecast to grow

TrendSpott

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is negative and it remained unchanged from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
TrendSpott
 

Bristol-Myers Squibb (BMY) has Low Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
February
 
S
M
T
W
T
F
S
 
March
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Options Activity
1 Day Ago
69.31
+1.61%
 
Options Activity
This Week
68.20
+0.03%
 
Investors Activity
3 Weeks Ago
68.00
-1.31%
 
Dividend Declares
3 Weeks Ago
69.30
+0.16%
 
Strong Earnings
2 Month Ago
72.77
+2.16%
 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss

 

Receive our daily BMY Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines